Phathom Pharmaceuticals, Inc. Total non-current assets

Total non-current assets of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current assets growth rates and interactive chart. The sum of all non-current or long-term assets.

Highlights and Quick Summary

  • Total non-current assets for the quarter ending June 29, 2021 was $3.24 Million (a -8.78% decrease compared to previous quarter)
  • Year-over-year quarterly Total non-current assets decreased by -13.06%
  • Annual Total non-current assets for 2020 was $3.74 Million (a 137.35% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current assets of Phathom Pharmaceuticals, Inc.

Most recent Total non-current assetsof PHAT including historical data for past 10 years.

Interactive Chart of Total non-current assets of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Total non-current assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $3.24 $3.55
2020 $3.74 $3.73 $3.74 $2.09 $3.74
2019 $1.58 $2.05 $1.58

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.